title: The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study.
abstract: OBJECTIVE
  To determine the effect of Escherichia coli Nissle (Mutaflor, Ardeypharm GmbH, Herdecke, Germany) on the intestinal colonization, level of endotoxin and liver functions in patients with liver cirrhosis.
  
  
  METHODS
  Thirty-nine patients with liver cirrhosis diagnosed by means of biopsy and clinical examinations were randomly allocated to treatment with E. coli Nissle or placebo for 42 days. Standard clinical examination, biochemical and hematological examinations, level of endotoxin and microbiological examination of the stool were performed before and after the treatment.
  
  
  RESULTS
  In comparing the treatment of E. coli Nissle and placebo, significant improvement of the intestinal colonization (P<0.001) in the E. coli Nissle group was described. We found a trend of significant lowering of the endotoxemia (P=0.07) and improvement of liver functions evaluated by Child-Pugh score (P=0.06).
  
  
  CONCLUSIONS
  E. coli Nissle seems to be effective in the restoration of normal colonic colonization and can probably lower endotoxemia in cirrhotic patients.
authors.affiliation: Department of Internal Medicine and Gastroenterology, University Hospital, Brno, Czech Republic. jlata@fnbrno.cz
authors.forename: Jan
authors.initials: J
authors.lastname: Lata
authors.forename: Ivo
authors.initials: I
authors.lastname: Novotný
authors.forename: Veronika
authors.initials: V
authors.lastname: Príbramská
authors.forename: Jana
authors.initials: J
authors.lastname: Juránková
authors.forename: Premysl
authors.initials: P
authors.lastname: Fric
authors.forename: Radek
authors.initials: R
authors.lastname: Kroupa
authors.forename: Oldrich
authors.initials: O
authors.lastname: Stibůrek
mesh_terms: D000328:Adult; D000368:Aged; D003106:Colon / Q000382:microbiology; D004311:Double-Blind Method; D019446:Endotoxemia / Q000150:complications / Q000628:therapy*; D004731:Endotoxins / Q000097:blood; D004926:Escherichia coli; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D008099:Liver / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D004731:Endotoxins